Clinical trial
A Study to Assess the Safety and Efficacy of Different AD 237 Doses in Adults…
NCT00242333 · Sosei, Industry · Completed
Key facts
| NCT number | NCT00242333 |
|---|---|
| Title | A Study to Assess the Safety and Efficacy of Different AD 237 Doses in Adults With COPD |
| Official title | A Multi-Center Randomized, Double-Blind, Parallel Group, Placebo Controlled Study, Including an Additional Open Label Tiotropium Group, to Assess the Efficacy, Safety and Tolerability of 4 Doses of AD 237 Inhaled Once Daily for 28 Days in Subjects With COPD. |
| Lead sponsor | Sosei, Industry |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | COPD |
| Intervention type | Drug |
| Interventions | AD 237 |
| Enrollment | 300 |
| Start date | Oct 1, 2005 |
| First posted | Oct 20, 2005 |
| Last update posted | May 16, 2006 |
| Countries | Bulgaria, Hungary, Poland, Romania |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: